RECRO PHARMA (REPH) Covered Calls

You can sell covered calls on RECRO PHARMA to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for REPH (prices last updated Mon 4:16 PM ET):

RECRO PHARMA (REPH) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
7.00 +0.34 6.67 7.11 213K - 0.1B
Covered Calls For RECRO PHARMA (REPH)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Oct 19 7.5 0.05 7.06 0.7% 51.1%
Nov 16 7.5 0.00 7.11 0.0% 0.0%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

Recro Pharma, Inc., a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company's lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain. It also develops Dex-IN, an intranasal formulation of dexmedetomidine for treating post-operative pain and peri-procedural pain; two novel neuromuscular blocking agents and a related proprietary chemical reversal agent; and Fadolmidine for use in as human therapeutic. The company also provides contract development and manufacturing services. Recro Pharma, Inc. has a license agreement with Orion Corporation for the development and commercialization of Dexmedetomidine. It focuses on offering its products for hospitals and related markets. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was founded in 2007 and is based in Malvern, Pennsylvania.